An IFNγ signature in bulk tumor tissue (which includes a complex mixture of cancer cells, stromal cells and immune cells etc.)has been associated with responsiveness to anti–PD-1 therapy in lung cancer and others malignancies (Ayers et al, 2017). The gene discussed is PDCD1; the disease is cancer.